BROOKLYN, N.Y. (Legal Newsline) - Two New York residents are suing the makers of a drug designed to treat infertility in women after the company recalled certain lots of the drug.
Angela Lauruska and Daniel Lauruska, both of Holtsville, New York, individually and for all others similarly situated, filed a class action lawsuit April 15 in U.S. District Court for the Eastern District of New York against Ferring Pharmaceuticals Inc., alleging breach of express and implied warranties, unjust enrichment, and violation of the New York General Business Law and similar laws in other states.
Ferring manufactures and sells Bravelle, a brand name version of the generic drug urofollitropin, designed to treat infertility in women. In October the company recalled certain lots of the drug that were lower in strength than specified, the suit says.
The lower strength of the drug resulted in a decreased therapeutic effect and the potential for increased dosage, side effects, and treatments with little or no chance of success, according to the complaint.
The suit alleges Ferring failed to take appropriate and necessary steps to ensure the affected Bravelle carried the specified potency and were effective in their intended use.
The Lauruskas and others in the class seek a jury trial, damages, interests, attorney fees and costs. They are represented by attorneys Andres F. Alonso and David B. Krangle of Alonso Krangle in Melville, New York.
U.S. District Court for the Eastern District of New York Case number 2:16-CV-01857-JFB-ARL